Fundies.
English

Segment disclosures

Company overview

MERIDIAN BIOSCIENCE INC

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

73 dimension combinations 771 retained observations 18 reported periods Partial retained history

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · Diagnostics

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-3042409000 USD20220805Open filing evidence
2022-01-01 – 2022-03-3141103000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3133204000 USD20220204Open filing evidence
2021-04-01 – 2021-06-3031189000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3093459000 USD20220805Open filing evidence
2021-01-01 – 2021-03-3131949000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3162270000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3130321000 USD20210205Open filing evidence
2019-10-01 – 2020-09-30121132000 USD20201123Open filing evidence
2020-04-01 – 2020-06-3021598000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3091331000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3134942000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3169733000 USD20210507Open filing evidence
2019-10-01 – 2019-12-3134791000 USD20210205Open filing evidence
2018-10-01 – 2019-09-30136682000 USD20201123Open filing evidence
2019-04-01 – 2019-06-3033118000 USD20200807Open filing evidence
2019-01-01 – 2019-03-3133500000 USD20200508Open filing evidence
2018-10-01 – 2018-12-3136665000 USD20200207Open filing evidence
2017-10-01 – 2018-09-30150454000 USD20201123Open filing evidence

Operating Segments · Life Science

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-04-01 – 2021-06-3032322000 USD20220805Open filing evidence
2020-10-01 – 2021-06-30148233000 USD20210806Open filing evidence
2021-01-01 – 2021-03-3153315000 USD20210507Open filing evidence
2020-10-01 – 2021-03-31115911000 USD20210507Open filing evidence
2020-10-01 – 2020-12-3162596000 USD20210205Open filing evidence
2019-10-01 – 2020-09-30132535000 USD20201123Open filing evidence
2020-04-01 – 2020-06-3063199000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3098183000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3122354000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3134984000 USD20210507Open filing evidence
2019-10-01 – 2019-12-3112630000 USD20210205Open filing evidence
2018-10-01 – 2019-09-3064332000 USD20201123Open filing evidence
2019-01-01 – 2019-03-3116748000 USD20200508Open filing evidence
2018-10-01 – 2018-12-3114815000 USD20200207Open filing evidence
2017-10-01 – 2018-09-3063117000 USD20201123Open filing evidence

Blood Chemistry Assays · Diagnostics

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vivo:BloodChemistryAssaysMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3014189000 USD20221122Open filing evidence
2021-10-01 – 2022-03-313503000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3178000 USD20220204Open filing evidence
2020-10-01 – 2021-09-3015398000 USD20221122Open filing evidence
2020-10-01 – 2021-06-3013006000 USD20220805Open filing evidence
2020-10-01 – 2021-03-318753000 USD20220506Open filing evidence
2020-10-01 – 2020-12-314394000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3017534000 USD20221122Open filing evidence
2019-04-01 – 2019-06-304750000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3013510000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-314330000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-318760000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-314466000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Gastrointestinal Assays · Diagnostics

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vivo:GastrointestinalAssaysMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3087568000 USD20221122Open filing evidence
2022-01-01 – 2022-03-3120281000 USD20220506Open filing evidence
2021-10-01 – 2022-03-3141900000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3121619000 USD20220204Open filing evidence
2020-10-01 – 2021-09-3068890000 USD20221122Open filing evidence
2020-10-01 – 2021-06-3048962000 USD20220805Open filing evidence
2020-10-01 – 2021-03-3131118000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3115452000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3055040000 USD20221122Open filing evidence
2020-04-01 – 2020-06-309584000 USD20200807Open filing evidence
2019-10-01 – 2020-06-3039644000 USD20200807Open filing evidence
2019-04-01 – 2019-06-3017232000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3052024000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-3116177000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3134792000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-3118633000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Immunoassays And Blood Chemistry Assays · Diagnostics

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vivo:ImmunoassaysAndBloodChemistryAssaysMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2019-04-01 – 2019-06-3027181000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3082912000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-3126368000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3155731000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-3129367000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Immunological Reagents · Life Science

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vivo:ImmunologicalReagentsMember;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3085299000 USD20221122Open filing evidence
2022-04-01 – 2022-06-3017619000 USD20220805Open filing evidence
2021-10-01 – 2022-06-3071096000 USD20220805Open filing evidence
2021-10-01 – 2021-12-3123649000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3059599000 USD20221122Open filing evidence
2021-04-01 – 2021-06-3011937000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3044217000 USD20220805Open filing evidence
2020-10-01 – 2020-12-3116567000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3054104000 USD20221122Open filing evidence
2019-04-01 – 2019-06-309827000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3029390000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-3111358000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3119565000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-318226000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Molecular Assays · Diagnostics

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vivo:MolecularAssaysMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3018177000 USD20221122Open filing evidence
2021-10-01 – 2022-06-3014039000 USD20220805Open filing evidence
2021-10-01 – 2022-03-319137000 USD20220506Open filing evidence
2021-10-01 – 2021-12-314752000 USD20220204Open filing evidence
2020-10-01 – 2021-09-3019037000 USD20221122Open filing evidence
2021-01-01 – 2021-03-314395000 USD20220506Open filing evidence
2020-10-01 – 2021-03-318985000 USD20220506Open filing evidence
2020-10-01 – 2020-12-314590000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3021907000 USD20221122Open filing evidence
2019-04-01 – 2019-06-305937000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3020371000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-317132000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3114434000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-317298000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Molecular Reagents · Life Science

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vivo:MolecularReagentsMember;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3091816000 USD20221122Open filing evidence
2022-04-01 – 2022-06-307743000 USD20220805Open filing evidence
2021-10-01 – 2022-03-3171822000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3131488000 USD20220204Open filing evidence
2020-10-01 – 2021-09-30130537000 USD20221122Open filing evidence
2020-10-01 – 2021-06-30104016000 USD20220805Open filing evidence
2021-01-01 – 2021-03-3137752000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3146029000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3078431000 USD20221122Open filing evidence
2019-04-01 – 2019-06-305495000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3017495000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-315390000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3111998000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-316589000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Non Molecular Assays · Diagnostics

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vivo:NonMolecularAssaysMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-3134876000 USD20230209Open filing evidence
2022-04-01 – 2022-06-3037533000 USD20220805Open filing evidence
2022-01-01 – 2022-03-3136718000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3128452000 USD20230209Open filing evidence
2020-10-01 – 2021-09-30108723000 USD20211123Open filing evidence
2021-04-01 – 2021-06-3026806000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3080091000 USD20210806Open filing evidence
2021-01-01 – 2021-03-3127554000 USD20210507Open filing evidence
2020-10-01 – 2021-03-3153285000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3125731000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3099225000 USD20211123Open filing evidence
2020-04-01 – 2020-06-3018416000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3074072000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3127704000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3155656000 USD20210507Open filing evidence
2019-10-01 – 2019-12-3127888000 USD20210205Open filing evidence
2018-10-01 – 2019-09-30110399000 USD20211123Open filing evidence
2017-10-01 – 2018-09-30116745000 USD20201123Open filing evidence

Other Diagnostics · Diagnostics

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vivo:OtherDiagnosticsMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3027514000 USD20221122Open filing evidence
2021-10-01 – 2022-06-3020891000 USD20220805Open filing evidence
2021-10-01 – 2021-12-315127000 USD20220204Open filing evidence
2020-10-01 – 2021-09-3025864000 USD20221122Open filing evidence
2021-01-01 – 2021-03-318239000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3113907000 USD20220506Open filing evidence
2020-10-01 – 2020-12-315669000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3021864000 USD20221122Open filing evidence
2019-04-01 – 2019-06-305428000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3016507000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-315440000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3111079000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-315589000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Respiratory Illness Assays · Diagnostics

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=vivo:RespiratoryIllnessAssaysMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3026632000 USD20221122Open filing evidence
2021-10-01 – 2022-06-3021359000 USD20220805Open filing evidence
2021-10-01 – 2022-03-3115871000 USD20220506Open filing evidence
2021-10-01 – 2021-12-316380000 USD20220204Open filing evidence
2020-10-01 – 2021-09-3017608000 USD20221122Open filing evidence
2020-10-01 – 2021-06-3012233000 USD20220805Open filing evidence
2020-10-01 – 2021-03-318492000 USD20220506Open filing evidence
2020-10-01 – 2020-12-314806000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3026694000 USD20221122Open filing evidence
2019-04-01 – 2019-06-305708000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3021242000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-317553000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3115534000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-317977000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

AU · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:AU;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-304312000 USD20221122Open filing evidence
2020-10-01 – 2021-09-309115000 USD20221122Open filing evidence
2019-10-01 – 2020-09-305957000 USD20221122Open filing evidence
2018-10-01 – 2019-09-303458000 RestatedUSD20211123Open filing evidence
2017-10-01 – 2018-09-303631000 RestatedUSD20201123Open filing evidence

BE · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:BE;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2018-10-01 – 2019-09-301465000 USD2019-11-26 · 13:38:53.000ZOpen filing evidence
2017-10-01 – 2018-09-301711000 RestatedUSD2019-11-26 · 13:38:53.000ZOpen filing evidence

CH · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:CH;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-301119000 USD20221122Open filing evidence
2020-10-01 – 2021-09-30632000 USD20221122Open filing evidence
2019-10-01 – 2020-09-30758000 USD20221122Open filing evidence

CN · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:CN;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3015368000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3013559000 USD20221122Open filing evidence
2019-10-01 – 2020-09-3019047000 USD20221122Open filing evidence
2018-10-01 – 2019-09-308464000 RestatedUSD20211123Open filing evidence
2017-10-01 – 2018-09-308347000 RestatedUSD20201123Open filing evidence

DE · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:DE;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3017969000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3018460000 USD20221122Open filing evidence
2019-10-01 – 2020-09-3014190000 USD20221122Open filing evidence
2018-10-01 – 2019-09-3012663000 RestatedUSD20211123Open filing evidence
2017-10-01 – 2018-09-308108000 RestatedUSD20201123Open filing evidence

ES · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:ES;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3011134000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3012593000 USD20221122Open filing evidence
2019-10-01 – 2020-09-307242000 USD20221122Open filing evidence
2018-10-01 – 2019-09-304414000 RestatedUSD20211123Open filing evidence
2017-10-01 – 2018-09-304187000 RestatedUSD20201123Open filing evidence

FI · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:FI;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2020-10-01 – 2021-09-301069000 USD20211123Open filing evidence
2019-10-01 – 2020-09-30275000 USD20211123Open filing evidence
2018-10-01 – 2019-09-30291000 USD20211123Open filing evidence

FI · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:FI;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3010317000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3017936000 USD20221122Open filing evidence
2019-10-01 – 2020-09-302518000 USD20221122Open filing evidence
2018-10-01 – 2019-09-30500000 USD20211123Open filing evidence
2017-10-01 – 2018-09-30467000 USD20201123Open filing evidence

FR · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:FR;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2018-10-01 – 2019-09-302442000 USD2019-11-26 · 13:38:53.000ZOpen filing evidence
2017-10-01 – 2018-09-302353000 RestatedUSD2019-11-26 · 13:38:53.000ZOpen filing evidence

FR · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:FR;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3011948000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3010733000 USD20221122Open filing evidence
2019-10-01 – 2020-09-305579000 USD20221122Open filing evidence
2018-10-01 – 2019-09-302200000 USD20211123Open filing evidence
2017-10-01 – 2018-09-302040000 RestatedUSD20201123Open filing evidence

GB · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:GB;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-303972000 USD20221122Open filing evidence
2020-10-01 – 2021-09-302197000 USD20221122Open filing evidence
2019-10-01 – 2020-09-302312000 USD20221122Open filing evidence
2018-10-01 – 2019-09-302396000 RestatedUSD20211123Open filing evidence
2017-10-01 – 2018-09-302340000 RestatedUSD20201123Open filing evidence

GB · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:GB;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3012882000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3013097000 USD20221122Open filing evidence
2019-10-01 – 2020-09-3014765000 USD20221122Open filing evidence
2018-10-01 – 2019-09-304709000 RestatedUSD20211123Open filing evidence
2017-10-01 – 2018-09-305201000 RestatedUSD20201123Open filing evidence

ID · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:ID;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2020-10-01 – 2021-09-305183000 USD20211123Open filing evidence
2019-10-01 – 2020-09-303027000 USD20211123Open filing evidence
2018-10-01 – 2019-09-30169000 USD20211123Open filing evidence
2017-10-01 – 2018-09-30162000 USD20201123Open filing evidence

IN · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:IN;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-301257000 USD20221122Open filing evidence
2020-10-01 – 2021-09-305558000 USD20221122Open filing evidence
2019-10-01 – 2020-09-302099000 USD20221122Open filing evidence
2018-10-01 – 2019-09-30143000 USD20211123Open filing evidence
2017-10-01 – 2018-09-30251000 USD20201123Open filing evidence

IT · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:IT;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-309741000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3012240000 USD20221122Open filing evidence
2019-10-01 – 2020-09-309797000 USD20221122Open filing evidence
2018-10-01 – 2019-09-3010911000 RestatedUSD20211123Open filing evidence
2017-10-01 – 2018-09-3010398000 RestatedUSD20201123Open filing evidence

IT · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:IT;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-303735000 USD20221122Open filing evidence
2020-10-01 – 2021-09-307516000 USD20221122Open filing evidence
2019-10-01 – 2020-09-304067000 USD20221122Open filing evidence
2018-10-01 – 2019-09-301357000 USD20211123Open filing evidence
2017-10-01 – 2018-09-30971000 USD20201123Open filing evidence

JP · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:JP;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2018-10-01 – 2019-09-301571000 USD2019-11-26 · 13:38:53.000ZOpen filing evidence
2017-10-01 – 2018-09-301307000 RestatedUSD2019-11-26 · 13:38:53.000ZOpen filing evidence

JP · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:JP;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-306591000 USD20221122Open filing evidence
2020-10-01 – 2021-09-306532000 USD20221122Open filing evidence
2019-10-01 – 2020-09-303707000 USD20221122Open filing evidence
2018-10-01 – 2019-09-301624000 USD20211123Open filing evidence
2017-10-01 – 2018-09-301932000 RestatedUSD20201123Open filing evidence

KR · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:KR;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3033642000 USD20221122Open filing evidence
2020-10-01 – 2021-09-309242000 USD20221122Open filing evidence
2019-10-01 – 2020-09-301908000 USD20221122Open filing evidence
2018-10-01 – 2019-09-301134000 USD20211123Open filing evidence
2017-10-01 – 2018-09-302044000 RestatedUSD20201123Open filing evidence

NL · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:NL;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2018-10-01 – 2019-09-301411000 USD2019-11-26 · 13:38:53.000ZOpen filing evidence
2017-10-01 – 2018-09-301454000 RestatedUSD2019-11-26 · 13:38:53.000ZOpen filing evidence

NL · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:NL;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2020-10-01 – 2021-09-303197000 USD20211123Open filing evidence
2019-10-01 – 2020-09-303212000 USD20201123Open filing evidence
2018-10-01 – 2019-09-30710000 USD20211123Open filing evidence
2017-10-01 – 2018-09-30715000 USD20201123Open filing evidence

PR · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:PR;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2018-10-01 – 2019-09-302276000 USD2019-11-26 · 13:38:53.000ZOpen filing evidence
2017-10-01 – 2018-09-301054000 USD2019-11-26 · 13:38:53.000ZOpen filing evidence

TR · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:TR;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-307858000 USD20221122Open filing evidence
2020-10-01 – 2021-09-307281000 USD20221122Open filing evidence
2019-10-01 – 2020-09-302819000 USD20221122Open filing evidence
2018-10-01 – 2019-09-30290000 USD20211123Open filing evidence
2017-10-01 – 2018-09-30188000 USD20201123Open filing evidence

US · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-30130101000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3099636000 USD20221122Open filing evidence
2019-10-01 – 2020-09-3095382000 USD20211123Open filing evidence
2018-10-01 – 2019-09-30107890000 RestatedUSD20201123Open filing evidence
2017-10-01 – 2018-09-30120555000 RestatedUSD2019-11-26 · 13:38:53.000ZOpen filing evidence

US · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2017-10-01 – 2018-09-3020442000 USD2018-11-29 · 13:39:44.000ZOpen filing evidence

CZK · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=currency:CZK;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-301926000 USD20221122Open filing evidence
2020-10-01 – 2021-09-30922000 USD20221122Open filing evidence
2019-10-01 – 2020-09-30601000 USD20221122Open filing evidence

Americas · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=srt:AmericasMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-30132175000 USD20221122Open filing evidence
2022-01-01 – 2022-03-3133551000 USD20220506Open filing evidence
2021-10-01 – 2022-03-3160164000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3126613000 USD20230209Open filing evidence
2020-10-01 – 2021-09-30101293000 USD20221122Open filing evidence
2021-04-01 – 2021-06-3024543000 USD20220805Open filing evidence
2020-10-01 – 2021-03-3148824000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3123551000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3097228000 USD20221122Open filing evidence
2020-04-01 – 2020-06-3017575000 USD20200807Open filing evidence
2019-10-01 – 2020-06-3072980000 USD20200807Open filing evidence
2020-01-01 – 2020-03-3127670000 USD20200508Open filing evidence
2019-10-01 – 2020-03-3155405000 USD20200508Open filing evidence
2019-10-01 – 2019-12-3127735000 USD20200207Open filing evidence
2019-04-01 – 2019-06-3027356000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3084042000 RestatedUSD20200807Open filing evidence
2019-01-01 – 2019-03-3126263000 RestatedUSD20200508Open filing evidence
2018-10-01 – 2019-03-3156686000 RestatedUSD20200508Open filing evidence
2018-10-01 – 2018-12-3130423000 RestatedUSD20200207Open filing evidence

Americas · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=srt:AmericasMember;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3033062000 USD20221122Open filing evidence
2021-10-01 – 2022-06-3025833000 USD20220805Open filing evidence
2022-01-01 – 2022-03-3110377000 USD20220506Open filing evidence
2021-10-01 – 2022-03-3118514000 USD20220506Open filing evidence
2021-10-01 – 2021-12-318137000 USD20220204Open filing evidence
2020-10-01 – 2021-09-3046063000 USD20221122Open filing evidence
2020-10-01 – 2020-12-3118755000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3037391000 USD20221122Open filing evidence
2019-04-01 – 2019-06-304369000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3014347000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-315453000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-319975000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-314534000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

EMEA · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-315694000 USD20230209Open filing evidence
2021-10-01 – 2022-09-3022135000 USD20221122Open filing evidence
2022-04-01 – 2022-06-303836000 USD20220805Open filing evidence
2022-01-01 – 2022-03-317113000 USD20220506Open filing evidence
2021-10-01 – 2022-03-3113206000 USD20220506Open filing evidence
2021-10-01 – 2021-12-316093000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3024475000 USD20221122Open filing evidence
2021-04-01 – 2021-06-306251000 USD20220805Open filing evidence
2020-10-01 – 2021-03-3112101000 USD20220506Open filing evidence
2020-10-01 – 2020-12-316020000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3021826000 USD20221122Open filing evidence
2019-04-01 – 2019-06-305076000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3015695000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-315535000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3110620000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-315085000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

EMEA · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:EMEAMember;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-316944000 USD20230209Open filing evidence
2021-10-01 – 2022-09-3081305000 USD20221122Open filing evidence
2022-04-01 – 2022-06-308200000 USD20220805Open filing evidence
2021-10-01 – 2022-03-3161894000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3128648000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3093655000 USD20221122Open filing evidence
2021-04-01 – 2021-06-3015723000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3070084000 USD20220805Open filing evidence
2020-10-01 – 2021-03-3154066000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3132311000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3058125000 USD20221122Open filing evidence
2019-04-01 – 2019-06-306389000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3021608000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-317901000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3115376000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-317455000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Other Countries · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=vivo:OtherCountriesMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-309699000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3010854000 RestatedUSD20221122Open filing evidence
2019-10-01 – 2020-09-3011018000 RestatedUSD20221122Open filing evidence
2018-10-01 – 2019-09-308295000 RestatedUSD20211123Open filing evidence
2017-10-01 – 2018-09-309282000 RestatedUSD20201123Open filing evidence

Other Countries · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=vivo:OtherCountriesMember;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-304607000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3012175000 RestatedUSD20221122Open filing evidence
2019-10-01 – 2020-09-3010589000 RestatedUSD20221122Open filing evidence
2018-10-01 – 2019-09-303244000 RestatedUSD20211123Open filing evidence
2017-10-01 – 2018-09-304405000 RestatedUSD20201123Open filing evidence

Other Foreign · Diagnostics

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=vivo:OtherForeignMember;us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-301593000 USD20221122Open filing evidence
2022-01-01 – 2022-03-31439000 USD20220506Open filing evidence
2021-10-01 – 2022-03-31937000 USD20220506Open filing evidence
2021-10-01 – 2021-12-31498000 USD20230209Open filing evidence
2020-10-01 – 2021-09-301992000 USD20221122Open filing evidence
2021-04-01 – 2021-06-30395000 USD20220805Open filing evidence
2020-10-01 – 2021-06-301740000 USD20220805Open filing evidence
2020-10-01 – 2020-12-31750000 USD20220204Open filing evidence
2019-10-01 – 2020-09-302078000 USD20221122Open filing evidence
2019-04-01 – 2019-06-30686000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-301806000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-31687000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-311120000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-31433000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Other Foreign · Life Science

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=vivo:OtherForeignMember;us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3062748000 USD20221122Open filing evidence
2021-10-01 – 2022-06-3054606000 USD20220805Open filing evidence
2021-10-01 – 2021-12-3118352000 USD20220204Open filing evidence
2020-10-01 – 2021-09-3050418000 USD20221122Open filing evidence
2020-10-01 – 2021-06-3038488000 USD20220805Open filing evidence
2020-10-01 – 2020-12-3111530000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3037019000 USD20221122Open filing evidence
2019-04-01 – 2019-06-304564000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-3010930000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2019-01-01 – 2019-03-313394000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-316212000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2018-12-312826000 USD2019-02-11 · 21:29:59.000ZOpen filing evidence

Diagnostics

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-3139366000 USD20230209Open filing evidence
2021-10-01 – 2022-09-30155903000 USD20221122Open filing evidence
2022-04-01 – 2022-06-3042409000 USD20220805Open filing evidence
2021-10-01 – 2022-06-30116716000 USD20220805Open filing evidence
2022-01-01 – 2022-03-3141103000 USD20220506Open filing evidence
2021-10-01 – 2022-03-3174307000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3133204000 USD20230209Open filing evidence
2020-10-01 – 2021-09-30127760000 USD20221122Open filing evidence
2021-04-01 – 2021-06-3031189000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3093459000 USD20220805Open filing evidence
2021-01-01 – 2021-03-3131949000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3162270000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3130321000 USD20220204Open filing evidence
2019-10-01 – 2020-09-30121132000 USD20221122Open filing evidence
2020-04-01 – 2020-06-3021598000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3091331000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3134942000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3169733000 USD20210507Open filing evidence
2019-10-01 – 2019-12-3134791000 USD20210205Open filing evidence
2018-10-01 – 2019-09-30136682000 USD20211123Open filing evidence
2019-04-01 – 2019-06-3033118000 USD20200807Open filing evidence
2018-10-01 – 2019-06-30103283000 USD20200807Open filing evidence
2019-01-01 – 2019-03-3133500000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3170165000 USD20200508Open filing evidence
2018-10-01 – 2018-12-3136665000 USD20200207Open filing evidence
2017-10-01 – 2018-09-30150454000 USD20201123Open filing evidence

Diagnostics · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-3139366000 USD20230209Open filing evidence
2021-10-01 – 2022-09-30155903000 USD20221122Open filing evidence
2021-10-01 – 2022-06-30116716000 USD20220805Open filing evidence
2021-10-01 – 2022-03-3174307000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3133204000 USD20230209Open filing evidence
2020-10-01 – 2021-09-30127760000 USD20221122Open filing evidence
2020-10-01 – 2020-12-3130321000 USD20220204Open filing evidence
2019-10-01 – 2020-09-30121132000 USD20221122Open filing evidence
2019-10-01 – 2020-06-3091331000 USD20200807Open filing evidence
2019-10-01 – 2020-03-3169733000 USD20200508Open filing evidence
2018-10-01 – 2019-09-30136682000 USD20211123Open filing evidence
2019-04-01 – 2019-06-3033118000 USD2019-08-07 · 12:15:18.000ZOpen filing evidence
2018-10-01 – 2019-06-30103283000 USD20200807Open filing evidence
2019-01-01 – 2019-03-3133500000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3170165000 USD20200508Open filing evidence

Diagnostics · Blood Chemistry Assays

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:ProductOrServiceAxis=vivo:BloodChemistryAssaysMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-314620000 USD20230209Open filing evidence
2022-04-01 – 2022-06-306431000 USD20220805Open filing evidence
2021-10-01 – 2022-06-309762000 USD20220805Open filing evidence
2022-01-01 – 2022-03-313425000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3178000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3015398000 USD20211123Open filing evidence
2021-04-01 – 2021-06-304254000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3013006000 USD20210806Open filing evidence
2021-01-01 – 2021-03-314358000 USD20220506Open filing evidence
2020-10-01 – 2021-03-318753000 USD20210507Open filing evidence
2020-10-01 – 2020-12-314394000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3017534000 USD20211123Open filing evidence
2020-04-01 – 2020-06-303364000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3012508000 USD20210806Open filing evidence
2020-01-01 – 2020-03-314194000 RestatedUSD20210507Open filing evidence
2019-10-01 – 2020-03-319142000 RestatedUSD20210507Open filing evidence
2019-10-01 – 2019-12-314951000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3018639000 RestatedUSD20211123Open filing evidence
2019-04-01 – 2019-06-304666000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3013364000 USD20200807Open filing evidence
2019-01-01 – 2019-03-314330000 USD20200508Open filing evidence
2018-10-01 – 2019-03-318760000 USD20200508Open filing evidence
2018-10-01 – 2018-12-314430000 USD20200207Open filing evidence
2017-10-01 – 2018-09-3019109000 USD20201123Open filing evidence

Diagnostics · Gastrointestinal Assays

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:ProductOrServiceAxis=vivo:GastrointestinalAssaysMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-3121273000 USD20230209Open filing evidence
2022-04-01 – 2022-06-3022715000 USD20220805Open filing evidence
2021-10-01 – 2022-06-3064704000 USD20220805Open filing evidence
2021-10-01 – 2021-12-3121619000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3068890000 USD20211123Open filing evidence
2021-04-01 – 2021-06-3017844000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3048962000 USD20210806Open filing evidence
2021-01-01 – 2021-03-3115666000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3131118000 USD20210507Open filing evidence
2020-10-01 – 2020-12-3115452000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3055040000 USD20211123Open filing evidence
2020-04-01 – 2020-06-309584000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3039644000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3114014000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3130060000 USD20210507Open filing evidence
2019-10-01 – 2019-12-3116251000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3068982000 RestatedUSD20211123Open filing evidence
2018-10-01 – 2019-06-3052024000 USD20200807Open filing evidence
2019-01-01 – 2019-03-3116177000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3134792000 USD20200508Open filing evidence
2018-10-01 – 2018-12-3118615000 USD20200207Open filing evidence
2017-10-01 – 2018-09-3078803000 USD20201123Open filing evidence

Diagnostics · Immunoassays And Blood Chemistry Assays

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:ProductOrServiceAxis=vivo:ImmunoassaysAndBloodChemistryAssaysMember
PeriodValueUnitFiledEvidence
2020-01-01 – 2020-03-3127704000 USD20200508Open filing evidence
2019-10-01 – 2020-03-3155656000 USD20200508Open filing evidence
2019-10-01 – 2019-12-3127904000 USD20200207Open filing evidence
2018-10-01 – 2019-09-30110451000 USD2019-11-26 · 13:38:53.000ZOpen filing evidence
2019-01-01 – 2019-03-3126416000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3155851000 USD20200508Open filing evidence
2018-10-01 – 2018-12-3129434000 USD20200207Open filing evidence
2017-10-01 – 2018-09-30116745000 USD2019-11-26 · 13:38:53.000ZOpen filing evidence

Diagnostics · Molecular Assays

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:ProductOrServiceAxis=vivo:MolecularAssaysMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-314490000 USD20230209Open filing evidence
2022-04-01 – 2022-06-304876000 USD20220805Open filing evidence
2022-01-01 – 2022-03-314385000 USD20220506Open filing evidence
2021-10-01 – 2021-12-314752000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3019037000 USD20211123Open filing evidence
2021-04-01 – 2021-06-304383000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3013368000 USD20220805Open filing evidence
2021-01-01 – 2021-03-314395000 USD20210507Open filing evidence
2020-10-01 – 2021-03-318985000 USD20210507Open filing evidence
2020-10-01 – 2020-12-314590000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3021907000 USD20211123Open filing evidence
2020-04-01 – 2020-06-303182000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3017259000 USD20210806Open filing evidence
2020-01-01 – 2020-03-317238000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3114077000 USD20210507Open filing evidence
2019-10-01 – 2019-12-316903000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3026283000 RestatedUSD20211123Open filing evidence
2019-04-01 – 2019-06-305894000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3020208000 USD20200807Open filing evidence
2019-01-01 – 2019-03-317084000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3114314000 USD20200508Open filing evidence
2018-10-01 – 2018-12-317231000 USD20200207Open filing evidence
2017-10-01 – 2018-09-3033709000 USD20201123Open filing evidence

Diagnostics · Nonmolecular Assays

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:ProductOrServiceAxis=vivo:NonmolecularAssaysMember
PeriodValueUnitFiledEvidence
2020-04-01 – 2020-06-3018416000 USD20200807Open filing evidence
2019-10-01 – 2020-06-3074072000 USD20200807Open filing evidence
2019-04-01 – 2019-06-3027224000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3083075000 USD20200807Open filing evidence

Diagnostics · Non Molecular Assays

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:ProductOrServiceAxis=vivo:NonMolecularAssaysMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-30137726000 USD20221122Open filing evidence
2021-10-01 – 2022-06-30102677000 USD20220805Open filing evidence
2021-10-01 – 2022-03-3165170000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3128452000 USD20220204Open filing evidence
2020-10-01 – 2021-09-30108723000 USD20221122Open filing evidence
2020-10-01 – 2021-06-3080091000 USD20220805Open filing evidence
2021-01-01 – 2021-03-3127554000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3125731000 USD20220204Open filing evidence
2019-10-01 – 2020-09-3099225000 USD20221122Open filing evidence

Diagnostics · Other Diagnostics

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:ProductOrServiceAxis=vivo:OtherDiagnosticsMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-316759000 USD20230209Open filing evidence
2022-04-01 – 2022-06-307775000 USD20220805Open filing evidence
2022-01-01 – 2022-03-317906000 USD20220506Open filing evidence
2021-10-01 – 2022-03-3113033000 USD20220506Open filing evidence
2021-10-01 – 2021-12-315127000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3025864000 USD20211123Open filing evidence
2021-04-01 – 2021-06-305349000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3019258000 USD20220805Open filing evidence
2021-01-01 – 2021-03-318239000 USD20210507Open filing evidence
2020-10-01 – 2021-03-3113907000 USD20210507Open filing evidence
2020-10-01 – 2020-12-315669000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3021864000 USD20211123Open filing evidence
2020-04-01 – 2020-06-303598000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3015515000 USD20210806Open filing evidence
2020-01-01 – 2020-03-315871000 RestatedUSD20210507Open filing evidence
2019-10-01 – 2020-03-3111919000 RestatedUSD20210507Open filing evidence
2019-10-01 – 2019-12-315811000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3022439000 RestatedUSD20211123Open filing evidence
2019-04-01 – 2019-06-305512000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3016653000 USD20200807Open filing evidence
2019-01-01 – 2019-03-315440000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3111079000 USD20200508Open filing evidence
2018-10-01 – 2018-12-315639000 USD20200207Open filing evidence
2017-10-01 – 2018-09-3023631000 USD20201123Open filing evidence

Diagnostics · Respiratory Illness Assays

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:ProductOrServiceAxis=vivo:RespiratoryIllnessAssaysMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-316714000 USD20230209Open filing evidence
2022-04-01 – 2022-06-305488000 USD20220805Open filing evidence
2022-01-01 – 2022-03-319491000 USD20220506Open filing evidence
2021-10-01 – 2021-12-316380000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3017608000 USD20211123Open filing evidence
2021-04-01 – 2021-06-303742000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3012233000 USD20210806Open filing evidence
2021-01-01 – 2021-03-313686000 USD20220506Open filing evidence
2020-10-01 – 2021-03-318492000 USD20210507Open filing evidence
2020-10-01 – 2020-12-314806000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3026694000 USD20211123Open filing evidence
2020-04-01 – 2020-06-305052000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3023664000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3110863000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3118612000 USD20210507Open filing evidence
2019-10-01 – 2019-12-317778000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3026622000 USD20211123Open filing evidence
2019-04-01 – 2019-06-305708000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3021242000 USD20200807Open filing evidence
2019-01-01 – 2019-03-317553000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3115534000 USD20200508Open filing evidence
2018-10-01 – 2018-12-317981000 USD20200207Open filing evidence
2017-10-01 – 2018-09-3028911000 USD20201123Open filing evidence

Diagnostics · BE

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:StatementGeographicalAxis=country:BE
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-301339000 USD20221122Open filing evidence
2020-10-01 – 2021-09-301554000 USD20221122Open filing evidence
2019-10-01 – 2020-09-301440000 USD20221122Open filing evidence
2018-10-01 – 2019-09-301468000 USD20211123Open filing evidence
2017-10-01 – 2018-09-301711000 USD20201123Open filing evidence

Diagnostics · FR

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:StatementGeographicalAxis=country:FR
PeriodValueUnitFiledEvidence
2020-10-01 – 2021-09-302283000 USD20211123Open filing evidence
2019-10-01 – 2020-09-302238000 USD20211123Open filing evidence
2018-10-01 – 2019-09-302446000 USD20211123Open filing evidence

Diagnostics · JP

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:StatementGeographicalAxis=country:JP
PeriodValueUnitFiledEvidence
2020-10-01 – 2021-09-30551000 USD20211123Open filing evidence
2019-10-01 – 2020-09-30848000 USD20211123Open filing evidence
2018-10-01 – 2019-09-301572000 USD20211123Open filing evidence

Diagnostics · NL

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:StatementGeographicalAxis=country:NL
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-301051000 USD20221122Open filing evidence
2020-10-01 – 2021-09-301279000 USD20221122Open filing evidence
2019-10-01 – 2020-09-301183000 USD20221122Open filing evidence
2018-10-01 – 2019-09-301413000 USD20211123Open filing evidence

Diagnostics · US

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2019-10-01 – 2020-09-3095382000 USD20221122Open filing evidence
2018-10-01 – 2019-09-30107890000 USD20211123Open filing evidence

Diagnostics · Americas

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:StatementGeographicalAxis=srt:AmericasMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-3133182000 USD20230209Open filing evidence
2022-04-01 – 2022-06-3038158000 USD20220805Open filing evidence
2021-10-01 – 2022-06-3098322000 USD20220805Open filing evidence
2020-10-01 – 2021-09-30101293000 USD20211123Open filing evidence
2021-04-01 – 2021-06-3024543000 USD20210806Open filing evidence
2020-10-01 – 2021-06-3073367000 USD20220805Open filing evidence
2021-01-01 – 2021-03-3125290000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3148824000 USD20210507Open filing evidence
2020-10-01 – 2020-12-3123551000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3097228000 USD20211123Open filing evidence
2020-04-01 – 2020-06-3017575000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3072980000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3127670000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3155405000 USD20210507Open filing evidence
2019-10-01 – 2019-12-3127735000 USD20210205Open filing evidence
2018-10-01 – 2019-09-30110109000 RestatedUSD20211123Open filing evidence

Diagnostics · EMEA

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-06-3017042000 USD20220805Open filing evidence
2020-10-01 – 2021-09-3024475000 USD20211123Open filing evidence
2021-04-01 – 2021-06-306251000 USD20210806Open filing evidence
2020-10-01 – 2021-06-3018352000 USD20220805Open filing evidence
2021-01-01 – 2021-03-316071000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3112101000 USD20210507Open filing evidence
2020-10-01 – 2020-12-316020000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3021826000 USD20211123Open filing evidence
2020-04-01 – 2020-06-303576000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3016853000 USD20210806Open filing evidence
2020-01-01 – 2020-03-316777000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3113277000 USD20210507Open filing evidence
2019-10-01 – 2019-12-316500000 USD20210205Open filing evidence
2018-10-01 – 2019-09-3023888000 RestatedUSD20211123Open filing evidence
2019-04-01 – 2019-06-305076000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3017427000 USD20200807Open filing evidence
2019-01-01 – 2019-03-316549000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3112351000 USD20200508Open filing evidence
2018-10-01 – 2018-12-315802000 USD20200207Open filing evidence

Diagnostics · Other Foreign

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:DiagnosticsMember;srt:StatementGeographicalAxis=vivo:OtherForeignMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-31490000 USD20230209Open filing evidence
2022-04-01 – 2022-06-30415000 USD20220805Open filing evidence
2021-10-01 – 2022-06-301352000 USD20220805Open filing evidence
2020-10-01 – 2021-09-301992000 USD20211123Open filing evidence
2021-04-01 – 2021-06-30395000 USD20210806Open filing evidence
2020-10-01 – 2021-06-301740000 USD20210806Open filing evidence
2021-01-01 – 2021-03-31588000 USD20220506Open filing evidence
2020-10-01 – 2021-03-311345000 USD20220506Open filing evidence
2020-10-01 – 2020-12-31750000 USD20210205Open filing evidence
2019-10-01 – 2020-09-302078000 USD20211123Open filing evidence
2020-04-01 – 2020-06-30447000 USD20210806Open filing evidence
2019-10-01 – 2020-06-301498000 USD20210806Open filing evidence
2020-01-01 – 2020-03-31495000 USD20210507Open filing evidence
2019-10-01 – 2020-03-311051000 USD20210507Open filing evidence
2019-10-01 – 2019-12-31556000 USD20210205Open filing evidence
2018-10-01 – 2019-09-302685000 RestatedUSD20211123Open filing evidence
2019-04-01 – 2019-06-30686000 USD20200807Open filing evidence
2018-10-01 – 2019-06-301814000 USD20200807Open filing evidence
2019-01-01 – 2019-03-31688000 USD20200508Open filing evidence
2018-10-01 – 2019-03-311128000 USD20200508Open filing evidence
2018-10-01 – 2018-12-31440000 USD20200207Open filing evidence

Life Science

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-3117536000 USD20230209Open filing evidence
2021-10-01 – 2022-09-30177115000 USD20221122Open filing evidence
2022-04-01 – 2022-06-3025362000 USD20220805Open filing evidence
2021-10-01 – 2022-06-30150627000 USD20220805Open filing evidence
2022-01-01 – 2022-03-3170128000 USD20220506Open filing evidence
2021-10-01 – 2022-03-31125265000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3155137000 USD20230209Open filing evidence
2020-10-01 – 2021-09-30190136000 USD20221122Open filing evidence
2021-04-01 – 2021-06-3032322000 USD20220805Open filing evidence
2020-10-01 – 2021-06-30148233000 USD20220805Open filing evidence
2021-01-01 – 2021-03-3153315000 USD20220506Open filing evidence
2020-10-01 – 2021-03-31115911000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3162596000 USD20220204Open filing evidence
2019-10-01 – 2020-09-30132535000 USD20221122Open filing evidence
2020-04-01 – 2020-06-3063199000 USD20210806Open filing evidence
2019-10-01 – 2020-06-3098183000 USD20210806Open filing evidence
2020-01-01 – 2020-03-3122354000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3134984000 USD20210507Open filing evidence
2019-10-01 – 2019-12-3112630000 USD20210205Open filing evidence
2018-10-01 – 2019-09-3064332000 USD20211123Open filing evidence
2019-04-01 – 2019-06-3015322000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3046885000 USD20200807Open filing evidence
2019-01-01 – 2019-03-3116748000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3131563000 USD20200508Open filing evidence
2018-10-01 – 2018-12-3114815000 USD20200207Open filing evidence

Life Science · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-3117536000 USD20230209Open filing evidence
2021-10-01 – 2022-09-30177115000 USD20221122Open filing evidence
2022-04-01 – 2022-06-3025362000 USD20220805Open filing evidence
2021-10-01 – 2022-06-30150627000 USD20220805Open filing evidence
2022-01-01 – 2022-03-3170128000 USD20220506Open filing evidence
2021-10-01 – 2022-03-31125265000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3155137000 USD20230209Open filing evidence
2020-10-01 – 2021-09-30190136000 USD20221122Open filing evidence
2020-10-01 – 2021-06-30148233000 USD20220805Open filing evidence
2021-01-01 – 2021-03-3153315000 USD20220506Open filing evidence
2020-10-01 – 2021-03-31115911000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3162596000 USD20220204Open filing evidence
2019-10-01 – 2020-09-30132535000 USD20221122Open filing evidence
2020-04-01 – 2020-06-3063199000 USD20200807Open filing evidence
2019-10-01 – 2020-06-3098183000 USD20200807Open filing evidence
2019-10-01 – 2020-03-3134984000 USD20200508Open filing evidence
2018-10-01 – 2019-09-3064332000 USD20211123Open filing evidence
2019-04-01 – 2019-06-3015322000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3046885000 USD20200807Open filing evidence
2019-01-01 – 2019-03-3116748000 USD2019-05-07 · 19:49:42.000ZOpen filing evidence
2018-10-01 – 2019-03-3131563000 USD20200508Open filing evidence

Life Science · Immunological Reagents

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember;srt:ProductOrServiceAxis=vivo:ImmunologicalReagentsMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-319962000 USD20230209Open filing evidence
2022-01-01 – 2022-03-3129794000 USD20220506Open filing evidence
2021-10-01 – 2022-03-3153443000 USD20220506Open filing evidence
2020-10-01 – 2021-09-3059599000 USD20211123Open filing evidence
2021-04-01 – 2021-06-3011937000 USD20210806Open filing evidence
2020-10-01 – 2021-06-3044217000 USD20210806Open filing evidence
2021-01-01 – 2021-03-3115563000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3132135000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3116567000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3054104000 USD20211123Open filing evidence
2020-04-01 – 2020-06-3024408000 RestatedUSD20210806Open filing evidence
2019-10-01 – 2020-06-3042480000 RestatedUSD20210806Open filing evidence
2020-01-01 – 2020-03-3110820000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3118082000 RestatedUSD20210507Open filing evidence
2019-10-01 – 2019-12-317263000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3041071000 USD20211123Open filing evidence
2019-04-01 – 2019-06-309827000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3029390000 USD20200807Open filing evidence
2019-01-01 – 2019-03-3111358000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3119565000 USD20200508Open filing evidence
2018-10-01 – 2018-12-318200000 USD20200207Open filing evidence

Life Science · Molecular Reagents

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember;srt:ProductOrServiceAxis=vivo:MolecularReagentsMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-317574000 USD20230209Open filing evidence
2021-10-01 – 2022-06-3079531000 USD20220805Open filing evidence
2022-01-01 – 2022-03-3140334000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3131488000 USD20230209Open filing evidence
2020-10-01 – 2021-09-30130537000 USD20211123Open filing evidence
2021-04-01 – 2021-06-3020385000 USD20220805Open filing evidence
2020-10-01 – 2021-06-30104016000 USD20210806Open filing evidence
2021-01-01 – 2021-03-3137752000 USD20210507Open filing evidence
2020-10-01 – 2021-03-3183776000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3146029000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3078431000 USD20211123Open filing evidence
2020-04-01 – 2020-06-3038791000 RestatedUSD20210806Open filing evidence
2019-10-01 – 2020-06-3055703000 RestatedUSD20210806Open filing evidence
2020-01-01 – 2020-03-3111534000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3116902000 RestatedUSD20210507Open filing evidence
2019-10-01 – 2019-12-315367000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3023261000 USD20211123Open filing evidence
2019-04-01 – 2019-06-305495000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3017495000 USD20200807Open filing evidence
2019-01-01 – 2019-03-315390000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3111998000 USD20200508Open filing evidence
2018-10-01 – 2018-12-316615000 USD20200207Open filing evidence

Life Science · CA

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember;srt:StatementGeographicalAxis=country:CA
PeriodValueUnitFiledEvidence
2020-10-01 – 2021-09-301073000 USD20211123Open filing evidence
2019-10-01 – 2020-09-30547000 USD20211123Open filing evidence
2018-10-01 – 2019-09-30322000 USD20211123Open filing evidence

Life Science · NL

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember;srt:StatementGeographicalAxis=country:NL
PeriodValueUnitFiledEvidence
2019-10-01 – 2020-09-303212000 USD20211123Open filing evidence
2018-10-01 – 2019-09-30710000 USD20201123Open filing evidence

Life Science · US

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-09-3032450000 USD20221122Open filing evidence
2020-10-01 – 2021-09-3044785000 USD20221122Open filing evidence
2019-10-01 – 2020-09-3036689000 USD20221122Open filing evidence
2018-10-01 – 2019-09-3018931000 RestatedUSD20211123Open filing evidence

Life Science · Americas

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember;srt:StatementGeographicalAxis=srt:AmericasMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-315859000 USD20230209Open filing evidence
2022-04-01 – 2022-06-307314000 USD20220805Open filing evidence
2021-10-01 – 2021-12-318137000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3046063000 USD20211123Open filing evidence
2021-04-01 – 2021-06-307419000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3039661000 USD20220805Open filing evidence
2021-01-01 – 2021-03-3113550000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3132296000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3118755000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3037391000 USD20211123Open filing evidence
2020-04-01 – 2020-06-3022007000 RestatedUSD20210806Open filing evidence
2019-10-01 – 2020-06-3030638000 RestatedUSD20210806Open filing evidence
2020-01-01 – 2020-03-314612000 USD20210507Open filing evidence
2019-10-01 – 2020-03-318623000 RestatedUSD20210507Open filing evidence
2019-10-01 – 2019-12-314012000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3019441000 RestatedUSD20211123Open filing evidence
2019-04-01 – 2019-06-304369000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3014347000 USD20200807Open filing evidence
2019-01-01 – 2019-03-315454000 USD20200508Open filing evidence
2018-10-01 – 2019-03-319976000 USD20200508Open filing evidence
2018-10-01 – 2018-12-314521000 USD20200207Open filing evidence

Life Science · EMEA

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember;srt:StatementGeographicalAxis=us-gaap:EMEAMember
PeriodValueUnitFiledEvidence
2021-10-01 – 2022-06-3070188000 USD20220805Open filing evidence
2022-01-01 – 2022-03-3133246000 USD20220506Open filing evidence
2020-10-01 – 2021-09-3093655000 USD20211123Open filing evidence
2021-04-01 – 2021-06-3015723000 USD20210806Open filing evidence
2020-10-01 – 2021-06-3070084000 USD20210806Open filing evidence
2021-01-01 – 2021-03-3121773000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3154066000 USD20210507Open filing evidence
2020-10-01 – 2020-12-3132311000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3058125000 USD20211123Open filing evidence
2020-04-01 – 2020-06-3026227000 RestatedUSD20210806Open filing evidence
2019-10-01 – 2020-06-3041305000 RestatedUSD20210806Open filing evidence
2020-01-01 – 2020-03-319946000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3114907000 RestatedUSD20210507Open filing evidence
2019-10-01 – 2019-12-314960000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3028850000 RestatedUSD20211123Open filing evidence
2019-04-01 – 2019-06-306389000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3021608000 USD20200807Open filing evidence
2019-01-01 – 2019-03-317852000 USD20200508Open filing evidence
2018-10-01 – 2019-03-3115213000 USD20200508Open filing evidence
2018-10-01 – 2018-12-317363000 USD20200207Open filing evidence

Life Science · Other Foreign

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=vivo:LifeScienceMember;srt:StatementGeographicalAxis=vivo:OtherForeignMember
PeriodValueUnitFiledEvidence
2022-10-01 – 2022-12-314733000 USD20230209Open filing evidence
2022-04-01 – 2022-06-309848000 USD20220805Open filing evidence
2022-01-01 – 2022-03-3126505000 USD20220506Open filing evidence
2021-10-01 – 2022-03-3144857000 USD20220506Open filing evidence
2021-10-01 – 2021-12-3118352000 USD20230209Open filing evidence
2020-10-01 – 2021-09-3050418000 USD20211123Open filing evidence
2021-04-01 – 2021-06-309180000 USD20220805Open filing evidence
2020-10-01 – 2021-06-3038488000 USD20210806Open filing evidence
2021-01-01 – 2021-03-3117992000 USD20220506Open filing evidence
2020-10-01 – 2021-03-3129549000 USD20220506Open filing evidence
2020-10-01 – 2020-12-3111530000 USD20210205Open filing evidence
2019-10-01 – 2020-09-3037019000 USD20211123Open filing evidence
2020-04-01 – 2020-06-3014965000 RestatedUSD20210806Open filing evidence
2019-10-01 – 2020-06-3026240000 RestatedUSD20210806Open filing evidence
2020-01-01 – 2020-03-317796000 USD20210507Open filing evidence
2019-10-01 – 2020-03-3111454000 RestatedUSD20210507Open filing evidence
2019-10-01 – 2019-12-313658000 RestatedUSD20210205Open filing evidence
2018-10-01 – 2019-09-3016041000 RestatedUSD20211123Open filing evidence
2019-04-01 – 2019-06-304564000 USD20200807Open filing evidence
2018-10-01 – 2019-06-3010930000 USD20200807Open filing evidence
2019-01-01 – 2019-03-313442000 USD20200508Open filing evidence
2018-10-01 – 2019-03-316374000 USD20200508Open filing evidence
2018-10-01 – 2018-12-312931000 USD20200207Open filing evidence